Vulnerable Populations and Emerging Interventions

Read this first

If you or someone you care for is pregnant, breastfeeding, a child, or living with a serious illness, do not start, stop or change a treatment on the basis of this page. Talk with the prescriber or treating team. If someone becomes seriously unwell after any procedure, get medical care right away; in the United States call 911 for an emergency.

This page is information only. It explains why some groups get extra protection in research and why they are often the targets of aggressive marketing. It makes no recommendation about any product.

Two different problems

"Vulnerable" can mean two things, and they are easy to mix up:

1. Research protections. Rules that add safeguards when people are enrolled in studies, because they may be more open to pressure or less able to judge risk.
2. Marketing and access. Some groups are more likely to be offered unproven products because they are desperate for options or because little evidence exists for them.

Evidence labels used here are explained in how we label evidence.

What US research rules say

The US federal human-subjects policy (45 CFR Part 46, current text read 2026-10-22) applies to research conducted, supported, or otherwise subject to regulation by a federal department or agency that adopts it. [1] A clinic selling a product raises a different question, about product approval, which the FDA addresses in its own notices.

The rules say that when subjects are likely to be vulnerable to coercion or undue influence, such as children, prisoners, individuals with impaired decision-making capacity, or economically or educationally disadvantaged persons, additional safeguards must be included in the study. [1] The policy has separate subparts with additional protections for pregnant women, fetuses and neonates (Subpart B), prisoners (Subpart C) and children (Subpart D). [1]

These subparts describe research approval. They do not mean an intervention is safe.

Children

The FDA's list of conditions for which regenerative medicine therapies have not been approved includes autism. [3] The same page warns that illegally marketed products can lead to infections, blindness and tumor formation. [3] See also children and teens. For research the rules cover, an ethics board must find that adequate provisions are made for the assent of the children and the permission of their parents or guardians. [1]

Serious or terminal illness

The ISSCR acknowledges that when no effective treatment exists, it is easy to understand why you may feel there is nothing to lose. [4] It says unproven treatments can create new health problems and that receiving one may make you ineligible for future clinical trials. [4] The EMA and the Heads of Medicines Agencies say unregulated advanced therapies are often sold as a "last hope," exploiting the worries of patients and their families. [5] The FDA warns that clinics may delay legitimate treatment, or cause harm, by offering unapproved exosome products with unsubstantiated claims. [6]

Other groups

• Older adults, people with disabilities, and people with limited resources: the research rules name impaired decision-making capacity and economic or educational disadvantage as reasons for added safeguards. [1] We did not find an official source that sets out age-specific rules for emerging interventions, so none are described.
• Identifiable communities in genetic research: the NHGRI notes that groups such as specific racial or ethnic groups, geographically defined communities and members of ultra-rare disease groups face unique privacy concerns. [7]

A practical frame

• Ask whether an intervention was ever tested in a group like yours. If not, "proven" claims may not apply.
• Ask who benefits financially. See financial conflicts in emerging health products.
• Ask about the consent process. See informed consent in emerging treatments.